RSS   Newsletter   Contact   Advertise with us

Passage Bio appoints Athena Countouriotis to board

Christian Fernsby | Philiadephia, Pa., USA | March 6, 2020
Athena CountouriotisPassage Bio, a genetic medicines company, announced the appointment of Athena Countouriotis to its board of directors.
Dr. Countouriotis is currently president and chief executive officer and a member of the Board of Directors at Turning Point Therapeutics.

Prior to joining Turning Point, Dr. Countouriotis was senior vice president and chief medical officer at Adverum Biotechnology and before that, at Halozyme Therapeutics.

Dr. Countouriotis has deep biotech leadership experience and currently is also a director at Iovance Biotherapeutics.

Dr. Countouriotis previously served as chief medical officer at Ambit Biosciences prior to its eventual acquisition by Daiichi Sankyo in 2014.

She also led various clinical development programs at Pfizer and Bristol Myers Squibb.

She received her residency training at University of California, Los Angeles as well as at Fred Hutchinson Cancer Research Center, where she focused on pediatric hematology and oncology.

Dr. Countouriotis earned her M.D. from Tufts University School of Medicine and holds a B.S. from the University of California, Los Angeles.


 LATEST MOVES FROM Pennsylvania 


MORE INSIDE POST